The Senate left Washington, D.C., Wednesday without addressing several key issues before the midterm elections. The upper ...

The performance data shown in tables and graphs on this page is calculated in GBX of the fund/index/average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ...

This Week's ThemeThere were three major changes this week.・Shifted from "upper limit exploration" of high C intake to ...

Heart disease is the leading cause of death in the U.S. Since researchers first established the link between diet, cholesterol, and heart disease in the 1950s, risk for heart disease has been partly ...

One in three babies are delivered by cesarean section in the U.S., the most common major surgery in this country. A new investigation by The New York Times finds that a widely-used fetal monitoring ...

A C-peptide test measures the amount of C-peptide present in the blood or urine. When the pancreas produces and releases the hormone insulin, it creates C-peptide in roughly equal amounts. Measuring C ...

Results demonstrated a confirmed overall response rate of 35% (95% CI, 24-46), all of which were partial responses. The Food and Drug Administration (FDA) has approved Emrelis ™ (telisotuzumab vedotin ...

The accelerated approval was based on data from the ongoing phase 2 LUMINOSITY study. The US Food and Drug Administration (FDA) has granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv) ...

Credit: AbbVie. The FDA approved the VENTANA MET (SP44) RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, locally advanced, or metastatic non-squamous non-small cell lung cancer ...